FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) has initiated a Phase I/II clinical study in the U.S. with its proprietary formulation of oral calcitonin for the treatment of osteoporosis. Twenty-four healthy postmenopausal women have been enrolled in the study, which will measure the effect of the drug on a well-established biochemical marker. The dosing is scheduled to be completed by the end of February.
